Anticoagulation in Cancer Related Stroke (OASIS-CANCER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02743052|
Recruitment Status : Recruiting
First Posted : April 19, 2016
Last Update Posted : April 19, 2016
|Condition or disease||Intervention/treatment|
|Cancer Stroke||Drug: Anticoagulation treatment.|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Optimal Anticoagulation Strategy In Stroke Related to CANCER (OASIS-CANCER Study)|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
- Drug: Anticoagulation treatment.
Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
- Recurrent stroke or systemic embolism [ Time Frame: up to 6 months ]Recurrent stroke (development of neurologic deterioration or a new symptom/sign and relevant new cerebral lesions documented by a neuroimaging study) or systemic embolism (objectively documented, symptomatic, recurrent deep-vein thrombosis, pulmonary embolism, or both ).
- 90-days modified Rankin Scale score [ Time Frame: examined at 90 days after stroke symptom onset in each patients ]
- Effect of anticoagulation treatment [ Time Frame: up to 14 days ]Effect of anticoagulation will be measured with D-dimer level during admission
- Symptomatic hemorrhagic transformation [ Time Frame: up to 6 months ]Symptomatic hemorrhagic transformation (newly developed cerebral hemorrhages that were temporally related to neurologic deterioration) or major bleeding up to 6 months (as defined by the International Society on Thrombosis and Haemostasis, J Thromb Haemost 2005;3:692-4)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02743052
|Contact: Jong-Won Chung, MD, MScfirstname.lastname@example.org|
|Korea, Republic of|
|Samsung Medical Center, Sungkyunkwan University School of Medicine||Recruiting|
|Seoul, Korea, Republic of, 135710|
|Contact: Jong-Won Chung, MD 82234101895 email@example.com|
|Principal Investigator: Oh Young Bang, MD|
|Sub-Investigator: Kwang Ho Lee, MD|
|Sub-Investigator: Chin-Sang Chung, MD|
|Sub-Investigator: Jong-Won Chung, MD|
|Principal Investigator:||Oh Young Bang, MD, PhD||Samsung Medical Center|